It may be possible to design drugs that mimic the positive health benefits of gut bacteria to treat diseases such as type II diabetes, a new study has found.
Johnson & Johnson’s Janssen pharma unit has announced new results showing that its Invokana diabetes medicine is the first in nearly 20 years to significantly reduce risk of renal failu
Express Scripts has announced a plan to cut patient co-pays for insulin products at $25 a month ahead of a pricing showdown with US politicians next week.
NICE has recommended that England’s NHS should routinely fund Merck, Sharpe, and Dohme’s type 2 diabetes drug Steglatro in a final decision, after the company undercut rivals from the same
Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023.